Agios adopts performance-based cash bonus for CMO tied to ENERGIZE trial milestone

AGIOS PHARMACEUTICALS, INC.

Dr. Sarah Gheuens, CMO and Head of R&D, eligible for up to 1.25x her 2022 target bonus ($309,375) if ENERGIZE trial milestone achieved by April 2024.
If milestone achieved before April 2024, bonus increases to 1.2x the baseline amount, totaling $371,250.
Bonus payment contingent on Dr. Gheuens remaining employed at time of milestone achievement.
CEO, CFO, and Chief Commercial Officer are not eligible for this bonus plan.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.